Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Head & Neck 2CNS 1

Conditions

Recurrence 2Nasopharyngeal Carcinoma 2Head and Neck Neoplasms 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Colorectal Neoplasms 1

Interventions

Cetuximab 14Cisplatin 12pembrolizumab 11Paclitaxel 9Gemcitabine 9durvalumab 6Nivolumab 6Docetaxel 6toripalimab 5Carboplatin 5Radiotherapy 4Fluorouracil 4Cyclophosphamide 4fludarabine 3Valproic Acid 3Capecitabine 3tremelimumab 2spartalizumab 2nimotuzumab 2irinotecan sucrosofate 2fludarabine phosphate 2cemiplimab 2anlotinib 2Sunitinib 2S 1 (combination) 2Radiation 2Oxaliplatin 2NVP-BKM120 2Methotrexate 2Ipilimumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recurrence × irinotecan sucrosofate × Head & Neck × Clear all
NCT07070479 2025-09-18

Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial

Sun Yat-sen University

Phase 2 Recruiting
208 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Neoplasm Metastasis, Recurrence

NCT06657690 2025-01-10

Irinotecan Liposome Combined with S-1 in PD-1/L1 Inhibitor Refractory Recurrent or Metastatic NPC

Sun Yat-sen University

Phase 2 Recruiting
56 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡